Annji Pharmaceutical Co (ROCO:7754) EPS (Basic): NT$-3.78 (TTM As of Dec. 2025)


ROCO:7754 Annji Pharmaceutical Co Ltd ROCO:7754
9 GF Score
Price NT$59.30
! 3 Warning Signs
View Full Analysis

What is Annji Pharmaceutical Co EPS (Basic)?

Annji Pharmaceutical Co ROCO:7754 -1.17% 9 EPS (Basic) is NT$-3.78 as of Dec. 2025. GuruFocus rates ROCO:7754 with a GF Score™ of 9/100. The stock has 3 warning signs investors should review.

Annji Pharmaceutical Co's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was NT$-2.09. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-3.78.

Annji Pharmaceutical Co's EPS (Diluted) for the six months ended in Dec. 2025 was NT$-2.09. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-3.78.

Annji Pharmaceutical Co's EPS without NRI for the six months ended in Dec. 2025 was NT$-2.09. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -3.78.

During the past 3 years, the average EPS without NRI Growth Rate was -1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Annji Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was -1.80% per year. The lowest was -21.50% per year. And the median was -11.65% per year.

Annji Pharmaceutical Co  (ROCO:7754) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Annji Pharmaceutical Co EPS (Basic) Related Terms

Annji Pharmaceutical Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Annji Pharmaceutical Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annji Pharmaceutical Co EPS (Basic) Chart

Annji Pharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
-2.11 -3.58 -4.22 -3.78 -3.78

Annji Pharmaceutical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial -1.81 -2.11 -1.67 -1.69 -2.09
ROCO:7754
9GF Score
Annji Pharmaceutical Co Ltd ROCO:7754
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annji Pharmaceutical Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Annji Pharmaceutical Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-357.869-0)/94.614
=-3.78

Annji Pharmaceutical Co's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-198.671-0)/94.725
=-2.10

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-3.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of NT$-3.78 mean?
Annji Pharmaceutical Co (ROCO:7754) has a EPS (Basic) of NT$-3.78 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Annji Pharmaceutical Co and its competitors.
Is Annji Pharmaceutical Co's EPS (Basic) too high?
Annji Pharmaceutical Co's current EPS (Basic) is NT$-3.78. Overall, Annji Pharmaceutical Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Annji Pharmaceutical Co's EPS (Basic) compare to VRTX and REGN?
Annji Pharmaceutical Co's EPS (Basic) of NT$-3.78 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Annji Pharmaceutical Co and its competitors. Annji Pharmaceutical Co's current EPS (Basic) is NT$-3.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annji Pharmaceutical Co stock overvalued right now?
Annji Pharmaceutical Co (ROCO:7754) has a current EPS (Basic) of NT$-3.78. The current EPS (Basic) is NT$-3.78. Annji Pharmaceutical Co's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Annji Pharmaceutical Co (ROCO:7754), the current EPS (Basic) is NT$-3.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annji Pharmaceutical Co Business Description

Address Zhongxiao E. Raod, 16th Floor-6, No. 508, Sector 7, Nangang Distrist, Taipei, TWN, 115011
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.
9GF Score

Get the complete analysis for ROCO:7754

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$59.30
Price